Triastek advances 3D printed drug D23 - a delayed-release budesonide tablet produced using Triastek’s proprietary MED - for IgAN treatment.

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent clinical study. D23 is budesonide ...

NANJING, China--(BUSINESS WIRE)--#3DPrintingPharmaceutical--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive ...

NANJING, China--(BUSINESS WIRE)--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent ...

Data from a new randomized, placebo-controlled trial have demonstrated the efficacy of budesonide in inducing remission of this disease; this study is an important contribution to this field.

Delays in receiving coverage for essential medications like insulin and albuterol can worsen symptoms, increase costs, and ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN ...

Methods Patients with COPD and ≥1 exacerbation in the previous 2 years were randomly assigned to open-label MART (Spiromax budesonide/formoterol 160/4.5 µg 2 inhalations twice daily+1 prn) or ...

If you're not happy with the results, please do another search.

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...